Compare SKYE & WHF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SKYE | WHF |
|---|---|---|
| Founded | 2012 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.9M | 162.2M |
| IPO Year | N/A | 2012 |
| Metric | SKYE | WHF |
|---|---|---|
| Price | $0.83 | $7.02 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 5 | 2 |
| Target Price | ★ $14.75 | $7.75 |
| AVG Volume (30 Days) | ★ 350.9K | 235.7K |
| Earning Date | 11-10-2025 | 11-10-2025 |
| Dividend Yield | N/A | ★ 26.33% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.42 |
| Revenue | N/A | ★ $76,339,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $15.98 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.82 | $6.39 |
| 52 Week High | $5.75 | $11.31 |
| Indicator | SKYE | WHF |
|---|---|---|
| Relative Strength Index (RSI) | 28.16 | 42.50 |
| Support Level | $0.82 | $6.76 |
| Resistance Level | $0.95 | $7.08 |
| Average True Range (ATR) | 0.11 | 0.20 |
| MACD | -0.01 | -0.08 |
| Stochastic Oscillator | 8.77 | 24.07 |
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
WhiteHorse Finance Inc is a non-diversified, closed-end management investment company. It makes debt investments in privately held; small-cap companies located in United States. Its investment objective is to generate risk-adjusted returns by originating and investing in senior secured loans, including first lien and second lien facilities, to performing lower middle market companies across a range of industries.